Surgery Partners stock
SGRYNASDAQSurgery Partners, Inc., HealthcareISIN US86881A1007
53Score 53 out of 100, Neutral
Price and trend
77 / 100
Price history
+68% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 77% above it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 97).
The price is at its 52-week high. Largest decline in 11 years: 83% (June 2021 to March 2026).
Chart figures for advanced users
- SMA 50$17.04
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$15.03
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)97
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$11.49
- The lowest closing price of the last twelve months.
- Resistance$26.73
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Surgery Partners, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $3.48B, is number 22 of 56 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.31B (up 6.2% year on year) and a loss of $77.9M.
- For fiscal 2026, analysts expect on average revenue of $3.23B (down 2.4%) and adjusted earnings per share of $0.36 (down 21.4%).
Show more
- MEQIRI Score 53 out of 100 (Neutral): rank 361 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 161% since 2020.Capital allocation 26
- Loss-makingLoss of $87M over the last 12 months.Fundamentals 44
- Interest barely coveredOperating profit covers interest only 1.4 times.Stability 43
Its standout strengths are momentum and valuation, while capital allocation and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 50 to 53.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- weak fundamentals
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
UndervaluedClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 2.2% on the twelve months before. Revenue has grown strongly since 2012, at around 22% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 23%, operating 12%, net −2%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 1 Mar 2027in 109 days
- Last reported
- 9 Nov 2026EPS reported $0.16 (expected $0.11)above expectations
Analyst estimates
- Earnings per share
- $0.36−10.7%
- Revenue
- $3.23B−3.5%
- Earnings per share
- $0.34−21.5%
- Revenue
- $3.01B−8.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −3.4%2026 guidance reaffirmed: revenue of $3.35 to $3.45 billion and adjusted EBITDA of at least $530 million; updated guidance after the Idaho Falls transaction closes.
“We are reaffirming our previously issued full year 2026 guidance for revenue of $3.35 billion to $3.45 billion and adjusted EBITDA of at least $530 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 10 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $304,713 in total.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Surgery Partners
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 53
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Option Care HealthOPCH $4.75B64
- Hims & Hers HealthHIMS $4.68B35
- MedicoverMCOV-B.ST $4.02B62
- Acadia HealthcareACHC $3.61B47
- National HealthCareNHC $3.3B68
- Guardian Pharmacy ServicesGRDN $3.16B77
- Aveanna Healthcare HoldingsAVAH $2.86B63
- Ardent HealthARDT $2.56B60
ETFs that hold Surgery Partners
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.07% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.07% | 0.30% | €2.17B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.07% | 0.30% | €185.82M |
Show 5 more
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.05% | 0.30% | €944.34M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.02% | 0.35% | €8.19B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 11 Nov 2026, previously Weak
- Valuation signal Undervalued since 12 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.